Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

Cytokeratin 5 antibody [EP1601Y]


Antibody ID


Target Antigen

Human Cytokeratin 5 human, mouse

Proper Citation

(Abcam Cat# ab52635, RRID:AB_869890)


monoclonal antibody


validation status unknown, seller recommendations provided in 2012: Immunocytochemistry; Immunohistochemistry; Western Blot; Immunocytochemistry, Immunohistochemistry-P, Western Blot

Clone ID

Clone EP1601Y

Host Organism




Cat Num


The GSK3 Signaling Axis Regulates Adaptive Glutamine Metabolism in Lung Squamous Cell Carcinoma.

  • Momcilovic M
  • Cancer Cell
  • 2018 May 14

Literature context:


Altered metabolism is a hallmark of cancer growth, forming the conceptual basis for development of metabolic therapies as cancer treatments. We performed in vivo metabolic profiling and molecular analysis of lung squamous cell carcinoma (SCC) to identify metabolic nodes for therapeutic targeting. Lung SCCs adapt to chronic mTOR inhibition and suppression of glycolysis through the GSK3α/β signaling pathway, which upregulates glutaminolysis. Phospho-GSK3α/β protein levels are predictive of response to single-therapy mTOR inhibition while combinatorial treatment with the glutaminase inhibitor CB-839 effectively overcomes therapy resistance. In addition, we identified a conserved metabolic signature in a broad spectrum of hypermetabolic human tumors that may be predictive of patient outcome and response to combined metabolic therapies targeting mTOR and glutaminase.

Funding information:
  • NIAMS NIH HHS - R01 AR061567(United States)

Simultaneous Multiplexed Imaging of mRNA and Proteins with Subcellular Resolution in Breast Cancer Tissue Samples by Mass Cytometry.

  • Schulz D
  • Cell Syst
  • 2018 Jan 24

Literature context:


To build comprehensive models of cellular states and interactions in normal and diseased tissue, genetic and proteomic information must be extracted with single-cell and spatial resolution. Here, we extended imaging mass cytometry to enable multiplexed detection of mRNA and proteins in tissues. Three mRNA target species were detected by RNAscope-based metal in situ hybridization with simultaneous antibody detection of 16 proteins. Analysis of 70 breast cancer samples showed that HER2 and CK19 mRNA and protein levels are moderately correlated on the single-cell level, but that only HER2, and not CK19, has strong mRNA-to-protein correlation on the cell population level. The chemoattractant CXCL10 was expressed in stromal cell clusters, and the frequency of CXCL10-expressing cells correlated with T cell presence. Our flexible and expandable method will allow an increase in the information content retrieved from patient samples for biomedical purposes, enable detailed studies of tumor biology, and serve as a tool to bridge comprehensive genomic and proteomic tissue analysis.

Funding information:
  • NIGMS NIH HHS - GM-047446(United States)

mTORC1 Activation during Repeated Regeneration Impairs Somatic Stem Cell Maintenance.

  • Haller S
  • Cell Stem Cell
  • 2017 Dec 7

Literature context:


The balance between self-renewal and differentiation ensures long-term maintenance of stem cell (SC) pools in regenerating epithelial tissues. This balance is challenged during periods of high regenerative pressure and is often compromised in aged animals. Here, we show that target of rapamycin (TOR) signaling is a key regulator of SC loss during repeated regenerative episodes. In response to regenerative stimuli, SCs in the intestinal epithelium of the fly and in the tracheal epithelium of mice exhibit transient activation of TOR signaling. Although this activation is required for SCs to rapidly proliferate in response to damage, repeated rounds of damage lead to SC loss. Consistently, age-related SC loss in the mouse trachea and in muscle can be prevented by pharmacologic or genetic inhibition, respectively, of mammalian target of rapamycin complex 1 (mTORC1) signaling. These findings highlight an evolutionarily conserved role of TOR signaling in SC function and identify repeated rounds of mTORC1 activation as a driver of age-related SC decline.

Funding information:
  • BLRD VA - I01 BX002324()
  • NCRR NIH HHS - UL1 RR024989(United States)
  • NHLBI NIH HHS - R01 HL132996()
  • NIA NIH HHS - K99 AG041764()
  • NIA NIH HHS - P01 AG036695()
  • NIA NIH HHS - R00 AG041764()
  • NIA NIH HHS - R01 AG047497()
  • NIA NIH HHS - R01 AG047820()
  • NIA NIH HHS - R37 AG023806()
  • NIDDK NIH HHS - R01 DK100342()
  • NIDDK NIH HHS - R01 DK113144()

Nfib Regulates Transcriptional Networks That Control the Development of Prostatic Hyperplasia.

  • Grabowska MM
  • Endocrinology
  • 2016 Mar 27

Literature context:


A functional complex consisting of androgen receptor (AR) and forkhead box A1 (FOXA1) proteins supports prostatic development, differentiation, and disease. In addition, the interaction of FOXA1 with cofactors such as nuclear factor I (NFI) family members modulates AR target gene expression. However, the global role of specific NFI family members has yet to be described in the prostate. In these studies, chromatin immunoprecipitation followed by DNA sequencing in androgen-dependent LNCaP prostate cancer cells demonstrated that 64.3% of NFIB binding sites are associated with AR and FOXA1 binding sites. Interrogation of published data revealed that genes associated with NFIB binding sites are predominantly induced after dihydrotestosterone treatment of LNCaP cells, whereas NFIB knockdown studies demonstrated that loss of NFIB drives increased AR expression and superinduction of a subset of AR target genes. Notably, genes bound by NFIB only are associated with cell division and cell cycle. To define the role of NFIB in vivo, mouse Nfib knockout prostatic tissue was rescued via renal capsule engraftment. Loss of Nfib expression resulted in prostatic hyperplasia, which did not resolve in response to castration, and an expansion of an intermediate cell population in a small subset of grafts. In human benign prostatic hyperplasia, luminal NFIB loss correlated with more severe disease. Finally, some areas of intermediate cell expansion were also associated with NFIB loss. Taken together, these results show a fundamental role for NFIB as a coregulator of AR action in the prostate and in controlling prostatic hyperplasia.

Funding information:
  • NINDS NIH HHS - R01 NS083898(United States)